Clinical trial
Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese…
NCT00148382 · Alizyme, Industry · Completed
Key facts
| NCT number | NCT00148382 |
|---|---|
| Title | Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects |
| Official title | Randomized, Double Blind, Parallel Group, Repeat Dose Pharmacokinetic and Pharmacodynamic Study of Four Doses of ATL-962 (40mg, 80mg, 120mg 240mg) in Otherwise-Healthy Obese Volunteers |
| Lead sponsor | Alizyme, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug |
| Interventions | ATL-962 |
| Enrollment | 80 |
| Start date | Apr 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 8, 2005 |
| Last update posted | Apr 11, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: